Chemo-Induced Ovarian Failure in Young Women with Breast Cancer
the Cancer Therapy Advisor take:
Ovarian toxicity may derive from acute vascular insult caused by chemotherapy in patients with breast cancer, according to an article published online in the journal The Oncologist.
Participants in this study included 20 patients (median age of 34 ± 5.24 years) diagnosed with localized breast cancer. Transvaginal ultrasound was used to evaluate the patients prior to initiation of chemotherapy, immediately following treatment completion, and at 6 and 12 months post-treatment.
Using resistance index and pulsatility index, the authors concluded that ovarian blood flow was significantly reduced immediately following chemotherapy treatment (P=0.01). Patients younger than 35 years significantly regained ovarian vasculature after 6 and 12 months post-treatment, compared with patients older than 35 years (P<0.05).
Furthermore, all patients experienced a significant drop in anti-Müllerian hormone (AMH) levels following treatment (P=0.04). At 12 months, 50% of patients resumed menses.
Results indicated that chemotherapy-induced ovarian toxicity may result from acute vascular insult caused by treatment.
The authors noted that ovarian vasculature impairment was diminished in patients who underwent a trastuzumab-based treatment, although results were not statistically significant (P=0.068).
The study suggests future research work to further understand and characterize patterns of chemotherapy-induced vascular toxicity for specific organs.
Ovarian toxicity may derive from acute vascular insult caused by chemotherapy in patients with breast cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer